KZRbenzinga

Kezar Life Sciences To Present Topline Results From The Portola Phase 2a Trial Evaluating Zetomipzomib For The Treatment Of Patients With Autoimmune Hepatitis On Tuesday, March 25, 2025

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 24, 2025 by benzinga